Arcus Biosciences, Inc.

RCUSNYSE • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
27.37 USD
↗ 0.73 (2.74%)AT CLOSE (11:59 AM EDT)
27.36
↘ 0.01 (0.04%)
POST MARKET (AS OF 04:32 PM EDT)
Post Market
AS OF 04:32 PM EDT
27.36
↘ 0.01 (0.04%)
🔴Market: CLOSED

RCUS is currently priced at $27.37. The technical outlook is "Neutral" and the fundamental picture shows "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 17, 2026.

Open?$26.01
High?$27.84
Low?$25.68
Prev. Close?$26.64
Volume?781.6K
Avg. Volume?1.4M
VWAP?$27.39
Rel. Volume?0.54x
Bid / Ask
Bid?$27.02 × 100
Ask?$32.98 × 100
Spread?$5.96
Midpoint?$30.00
Valuation & Ratios
Market Cap?3.4B
Shares Out?125.8M
Float?88.7M
Float %?70.8%
P/E Ratio?N/A
P/B Ratio?6.39
EPS?-$2.93
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
601
Market Cap
3.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.arcusbio.com
Listed
2018-03-15
Address
3928 POINT EDEN WAY
HAYWARD, CA 94545
Phone: (510) 694-6200
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
25
Momentum?
50
Short Sent.?
60
Piotroski F-Score?0/9Weak
Altman Z-Score?1.67Distress
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?14.26%High
Short Interest?12.6M
Days to Cover?5.9
Free Float88.7M
Avg Daily Volume2.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?4.04Strong
Quick Ratio?4.04Strong
Cash Ratio?0.96Adequate
Debt/Equity?0.19Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
29
6.39FAIR▾
P/S?
Peers
100
S&P
3
14.20HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-8.3CHEAP▾
EV/Sales?
Peers
100
S&P
3
13.77HIGH▾
Returns & Efficiency
ROE?
S&P
3
-70.4%WEAK▾
ROA?
S&P
3
-37.0%WEAK▾
Cash Flow & Enterprise
FCF?$-356000000
Enterprise Value?$3.2B
Fundamentals ratios updated end of day
MarketsMoversWatchlist